MedTrace Logo

Whole Body Vibration Versus Aerobic Training on Interleukin 6 and Endurance After Renal Transplantation

NCT07333105 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-13

No results posted yet for this study

Summary

This study aimed to compare the effect of whole body vibration versus aerobic training on interleukin 6 and endurance after renal transplantation in patients after renal transplantation.

Conditions

  • Whole Body Vibration
  • Aerobic Training
  • Interleukin 6
  • Endurance
  • Renal Transplantation

Interventions

DEVICE

whole body vibration

In a structured exercise session, subjects are instructed not to eat 2 hours prior and to wear comfortable clothing. They will rest for 10-15 minutes before starting, and will be barefoot to allow for proper vibration effects from the force platform, which induces lateral body oscillations. Before commencing, all parts of the whole-body vibration (WBV) device are checked for presence and functionality. The initial phase includes a 5-10 minute warm-up of stretching and marching. Over a 12-week period, subjects will undergo five 2-minute vibration treatments at 30 Hz, three times a week, followed by a 5-minute cool down. Participants are to stand upright with slightly flexed knees, ensuring their body alignment is maintained. Hand bars are available for those who feel insecure during the exercise.

DEVICE

stationary bicycle

Thirty patients will undergo a supervised exercise program on a stationary bicycle for 12 weeks, exercising three times weekly. Each session will include a 5-minute warm-up (light walking), a 10-minute active phase (biking), and a 5-minute cool down (light walking). The total duration will be 20 minutes, with exercise intensity set at 60-70% of maximum heart rate, calculated using the Karvonen formula (maximum heart rate=220-Age). The walking speed will gradually increase from 60% to 70% of maximum heart rate over the course of the study.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-01-01
Completion
2025-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07333105 on ClinicalTrials.gov